More than 50 years have passed since the use of L-dopa in the palliative treatment of Parkinson's disease, but it remains the most common treatment despite inducing severe side effects such as dyskinesia after 4-6 years of use. Numerous preclinical investigations based on endogenous neurotoxin models have promised various therapies for Parkinson's disease, but these efforts have failed when attempting to transfer these successful results to preclinical studies. Although several publications have warned of these failures, the scientific community remains mostly unaware, and there is a need to…mehr
More than 50 years have passed since the use of L-dopa in the palliative treatment of Parkinson's disease, but it remains the most common treatment despite inducing severe side effects such as dyskinesia after 4-6 years of use. Numerous preclinical investigations based on endogenous neurotoxin models have promised various therapies for Parkinson's disease, but these efforts have failed when attempting to transfer these successful results to preclinical studies. Although several publications have warned of these failures, the scientific community remains mostly unaware, and there is a need to focus their efforts on potential therapeutics that can slow or halt development of the disease.
Clinical Studies and Therapies in Parkinson's Disease: Translations from Preclinical Models analyzes preclinical models based on exogenous neurotoxins and why they have failed. Neuroscientists, neurologists, and neuropharmacologists will benefit greatly from the book's discussion of these newer models, their benefits, and the need for their implementation. This book also provides the basic concepts of dopamine metabolism for students taking courses in neurochemistry, neuroscience, neuropharmacology, biochemistry, and medicine.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Dr. Juan Segura-Aguilar, PhD, is a professor of molecular and clinical pharmacology at the University of Chile, Santiago, Chile. He obtained his PhD in biochemistry from Stockholm University, Stockholm, Sweden in 1989. He was previously an associate professor at Uppsala University, Uppsala, Sweden. In 1998, he began as an associate professor at University of Chile, and since 2001 has been a full professor. His research has been focused on mechanisms involved in dopaminergic neuron degeneration in Parkinson¿s disease. He has more than 140 publications of his research work on neurodegenerative disorders.
Inhaltsangabe
1. Parkinson's disease 2. Parkinson´s pharmacological therapy 3. Dopamine synthesis 4. Dopamine storage and release 5. Dopamine oxidative deamination 6. Dopamine methylation 7. Dopamine oxidation to neuromelanin and neurotoxic metabolites 8. Neuroprotective mechanisms against dopamine oxidation-dependent neurotoxicity 9. Preclinical model based on exogenous neurotoxins for Parkinson's disease 10. Preclinical models based on genetic mutations associated with the familial form of Parkinson´s disease 11. Preclinical models based on endogenous neurotoxins 12. Conclusions
1. Parkinson's disease 2. Parkinson´s pharmacological therapy 3. Dopamine synthesis 4. Dopamine storage and release 5. Dopamine oxidative deamination 6. Dopamine methylation 7. Dopamine oxidation to neuromelanin and neurotoxic metabolites 8. Neuroprotective mechanisms against dopamine oxidation-dependent neurotoxicity 9. Preclinical model based on exogenous neurotoxins for Parkinson's disease 10. Preclinical models based on genetic mutations associated with the familial form of Parkinson´s disease 11. Preclinical models based on endogenous neurotoxins 12. Conclusions
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826